Skip to main content

Oprelvekin Dosage

Applies to the following strengths: 5 mg

Usual Adult Dose for Thrombocytopenia Drug Induced

50 mcg/kg subcutaneously once a day starting 6 to 24 hours after chemotherapy completion

Duration of therapy: Until the post-nadir platelet count is 50,000/mcL or greater up to 6 cycles following chemotherapy; dosing beyond 21 days is not recommended; discontinue treatment at least 2 days before starting the next planned chemotherapy cycle.


Use: Prevention of severe thrombocytopenia and reduction of the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.

Renal Dose Adjustments

Mild to moderate renal dysfunction (CrCl 30 mL/min or greater): No adjustment recommended
Severe renal dysfunction (CrCl less than 30 mL/min): Reduce dose by 50%

Liver Dose Adjustments

Data not available



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:

Reconstitution/preparation techniques: The manufacturer product information should be consulted.



Patient advice:

More about oprelvekin

Patient resources

Other brands


Professional resources

Other brands


Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.